Home  /   Products  /   Urology  /   Antibodies to endothelial NO-synthase (Afalaza) – [100 lozenges]

Antibodies to endothelial NO-synthase (Afalaza) – [100 lozenges]

$37.26

Drug for the treatment of benign prostatic hyperplasia

SKU: 61041 Category:

Description

Afalase Pharmacodynamics
It is experimentally and clinically shown that antibodies to prostate specific antigen (PSA) affinity purified modify functional activity of endogenous PSA, which is changed at benign prostatic hyperplasia, that is accompanied by strengthening of regulatory influence of this antigen on functional and metabolic processes in prostate tissue, have a pronounced anti-inflammatory and anti-edema effect.
Antibodies to endothelial NO-synthase affinity purified promotes increase of a blood flow rate, including in vessels of a penis and prostate; has protective action in relation to endothelium (promotes decrease in reactivity of vessels, reduction of vascular spasm and improvement of peripheral microcirculation). Combined use of the components in the complex preparation Afalase is accompanied by a synergistic effect: antibodies to endothelial NO synthase enhance antiproliferative and anti-inflammatory activity of antibodies to PSA due to their endothelioprotective effect and improvement of vascularization. The synergistic effect is probably also due to nonspecific mechanisms of enhancing intracellular signal transduction by dilutions of antibodies to endothelial NO synthase.
In patients with BPH, if used for 12 months, the drug promotes reduction of the prostate volume, improvement of urodynamic parameters (decrease of residual urine volume, increase of maximum urine velocity), significant reduction of dysuric disorders, without influencing PSA level.
The drug improves the quality of life of patients with benign prostatic hyperplasia (BPH).
Expressed anti-inflammatory and anti-edematous action of the drug is shown experimentally. The drug promotes normalization of the functional state of the prostate and lower urinary tracts, improvement of urodynamic parameters (decrease of residual urine volume, increase of maximum urine velocity), normalization of PSA level.

Indications
Benign prostatic hyperplasia.
Dysuric disorders (in the treatment): frequent urge to urination, difficulty in urination, pain and discomfort in the perineum.

Contraindications .
Increased individual sensitivity to the components of the drug.
Pregnancy and lactation
The drug Afalaza not intended for use in women.

Dosage and administration

  • Inside. Take 2 tablets 2 times a day, in the morning and in the evening (keep in the mouth until complete dissolution – after meals).
  • With dysuric disorders drug is recommended to take 16 weeks.
  • On the recommendation of the doctor at the expressed pain syndrome and dysuric disorders in the first 2-3 weeks of therapy administration of the drug up to 4 times a day is indicated.
  • To prevent prostatic gland growth in patients with BPH and to reduce the risk of disease progression, it is recommended to take the drug 2 times a day, in the morning and in the evening during 12 months.